Clinical Research Directory

Inclusion Criteria: * Histology or cytology proven non-haematological cancer. * At least one lesion in the bones is required. * ECOG performance status ≤ 2. * ≥ 18 years old. * Life expectancy \> 6 months. * GTV diameter ≤ 5 cm. * In case of de novo OMD and OMD recurrence a maximum of 5 targets (including the primary tumour) in a maximum of 3 organ sites are allowed. * In case of OPD \* and induced OMD\*2 only 3 metastases (including the primary tumour) are allowed. * The metastatic lesion(s) must be visible on a CT- or MR- scan and suitable for treatment with SABR. * All metastatic sites are treated or planned for ablative therapy (including surgery) - for OPD only the sites in progression is required to fulfil this criterion. • A baseline scan within 28 days of inclusion (CT or PET- CT). * For spine/paraspinal targets, an MR scan is mandatory, if epidural growth cannot be precluded on the baseline CT scan. * No curative intended treatment option available. * An ablative strategy should be deemed clinically relevant and is at the discretion of the treating physician to decide. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patient cannot tolerate physical set up required for SABR. * Uncontrolled intercurrent illness. * Pregnancy. * Bilsky score ≥ 1b. If the patient is treated with surgery, a pre-operative Bilsky score ≥ 1b is an exclusion criterion as well. See appendix A for Bilsky score. * Presence of myelopathy from the target area. * Candidate for surgical treatment (determined by the institutions clinical oncologist, neurosurgeon or orthopaedic surgeon). * For spine/paraspinal lesions where epidural growth cannot be precluded on the baseline CT scan: patients for whom an MR scan is contraindicated. * Mechanical instability and/or fracture risk \*3. * For spine disease, involvement of ≥ three contiguous vertebrae. * Uncontrolled disease in respect to malignant pleural effusion, ascites, lymphangitic carcinomatosis, pleural carcinomatosis or peritoneal carcinomatosis. * Patients with uncontrolled brain metastases. * If the patient has received previous radiotherapy, the combined dose at the radiation site must not exceed the dose constraints according to Appendix B. -